{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-020586","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.253466+00:00","generated_at":"2026-05-15T00:37:05.700599+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cocrystal Pharma presents CDI-988 data at ICAR 2026; Phase 1b norovirus study fully enrolled in stage 1","bullets":["CDI-988 mechanism and Phase 1b human challenge study featured at ICAR 2026 in Prague.","Phase 1b study fully enrolled first cohort to assess infectivity of GII.2 Snow Mountain Virus inoculum.","CDI-988 is first oral direct-acting antiviral for norovirus; targets conserved 3CL protease across strains.","FDA Fast Track designation granted for CDI-988 for norovirus treatment and prophylaxis.","No approved treatments or vaccines for norovirus; $60 billion annual economic burden."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-020586","json":"https://secwatch.observer/filing/0001493152-26-020586.json","markdown":"https://secwatch.observer/filing/0001493152-26-020586.md","text":"https://secwatch.observer/filing/0001493152-26-020586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226020586/0001493152-26-020586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226020586/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:37:05.700599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}